Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc

SG&A Expenses: Madrigal vs. Verona, 2014-2023

__timestamp	Madrigal Pharmaceuticals, Inc.	Verona Pharma plc
Wednesday, January 1, 2014	15746000	1802274
Thursday, January 1, 2015	13392000	2512761
Friday, January 1, 2016	9290000	2894488
Sunday, January 1, 2017	7672000	8096274
Monday, January 1, 2018	15293000	7985229
Tuesday, January 1, 2019	22648000	8994597
Wednesday, January 1, 2020	21864000	29772000
Friday, January 1, 2021	37318000	33907000
Saturday, January 1, 2022	48130000	26579000
Sunday, January 1, 2023	108146000	49868547

Unlocking the unknown

A Tale of Two Pharmaceuticals: SG&A Expenses Over Time

In the competitive world of pharmaceuticals, managing costs is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Verona Pharma plc from 2014 to 2023. Over this period, Madrigal Pharmaceuticals saw a staggering increase in SG&A expenses, growing by nearly 587% from 2014 to 2023. In contrast, Verona Pharma's expenses rose by approximately 2,667% during the same period, reflecting their aggressive expansion strategy.

Key Insights

2014-2017: Madrigal maintained relatively stable expenses, while Verona's costs began to climb.
2018-2020: Both companies experienced significant growth in expenses, with Verona surpassing Madrigal in 2020.
2021-2023: Madrigal's expenses surged, reaching over twice that of Verona by 2023.

These trends underscore the dynamic nature of the pharmaceutical industry and the strategic decisions companies must make to balance growth and cost management.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc

Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared

Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.

Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc

Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc

Analyzing R&D Budgets: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc

Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.

Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.

Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared

Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?

Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.